Senseonics (NYSE:SENS) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Senseonics (NYSE:SENS) in a report issued on Thursday morning. The brokerage issued a sell rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $2.00 price target on shares of Senseonics in a report on Friday, November 15th.

Senseonics Stock Performance

NYSE:SENS opened at $0.59 on Thursday. Senseonics has a 52-week low of $0.25 and a 52-week high of $0.75. The business’s fifty day moving average is $0.36 and its 200 day moving average is $0.38. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47. The firm has a market cap of $352.55 million, a price-to-earnings ratio of -4.56 and a beta of 0.77.

Insider Activity

In related news, CEO Timothy T. Goodnow purchased 315,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The stock was acquired at an average price of $0.31 per share, with a total value of $97,650.00. Following the purchase, the chief executive officer now directly owns 11,310,355 shares in the company, valued at approximately $3,506,210.05. This represents a 2.86 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Frederick T. Sullivan acquired 124,933 shares of the stock in a transaction dated Thursday, December 12th. The shares were bought at an average price of $0.38 per share, for a total transaction of $47,474.54. Following the transaction, the chief financial officer now owns 2,478,844 shares in the company, valued at approximately $941,960.72. This represents a 5.31 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Symmetry Partners LLC purchased a new stake in Senseonics in the third quarter worth approximately $164,000. GSA Capital Partners LLP purchased a new stake in shares of Senseonics in the 3rd quarter valued at $117,000. Geode Capital Management LLC grew its holdings in shares of Senseonics by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock valued at $2,042,000 after purchasing an additional 179,103 shares during the last quarter. FMR LLC grew its holdings in shares of Senseonics by 48,267.2% during the 3rd quarter. FMR LLC now owns 168,318 shares of the company’s stock valued at $59,000 after purchasing an additional 167,970 shares during the last quarter. Finally, Cubist Systematic Strategies LLC raised its position in Senseonics by 25.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock worth $166,000 after purchasing an additional 85,501 shares during the period. 12.36% of the stock is currently owned by hedge funds and other institutional investors.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.